AIM ImmunoTech Inc.: ceo Thomas K Equels bought 31,250 shares

What happened The filing reports that Thomas K Equels, ceo, president and director, purchased 31,250 shares at $0.16 per share on Oct 22, 2026, for $5,094.

Key details

• Transaction date and price: Oct 22, 2026 at $0.16 per share (transaction code P, purchase — open market or private purchase).
• Shares acquired: 31,250; aggregate purchase price: $5,094.
• Amount beneficially owned following the reported transaction: not stated in the filing.
• Footnotes or plan info: the filing does not report any footnotes or a 10b5-1 plan.
• Filing date: filed with the SEC on Oct 23, 2026; the filing does not indicate it was late.

Why it may matter

• This entry is a purchase reported under transaction code P (open market or private purchase). A filing does not show why the insider traded or why the company acted.